Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Purchase of marketable securities | (203,644) | (281,194) |
| Proceeds from maturities of marketable securities | 289,105 | 235,957 |
| Proceeds from sale of marketable securities | 3,384 | 7,003 |
| Purchases of property and equipment | (383) | (1,358) |
| Net cash provided by (used in) investing activities | 88,462 | (39,592) |
| Cash Flows from Financing Activities | ||
| Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan | 33,117 | 14,847 |
| Tax withholding payments related to net settlement of restricted stock units | — | (479) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Protagonist Therapeutics's capex?
- Protagonist Therapeutics (PTGX) reported capex of $168K in Q2 2026.
- How has Protagonist Therapeutics's capex changed year-over-year?
- Protagonist Therapeutics's capex decreased by 79.3% year-over-year, from $813K to $168K.
- What is the long-term trend for Protagonist Therapeutics's capex?
- Over 4 years (2021 to 2025), Protagonist Therapeutics's capex has grown at a 9.6% compound annual growth rate (CAGR), from $1.1M to $1.59M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Protagonist Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude